155 related articles for article (PubMed ID: 35833564)
1. Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.
Keri J; Cook-Bolden FE; Green L; Kircik LH; Baldwin H; Werschler WP; Guenin E; Pillai R; Bhatt V
J Dermatolog Treat; 2022 Sep; 33(6):2790-2799. PubMed ID: 35833564
[TBL] [Abstract][Full Text] [Related]
2. Randomized tolerability analysis of clindamycin phosphate 1.2%-tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris.
Draelos ZD; Potts A; Alió Saenz AB;
Cutis; 2010 Dec; 86(6):310-8. PubMed ID: 21284283
[TBL] [Abstract][Full Text] [Related]
3. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.
Tanghetti EA; Zeichner JA; Gold M; Sadick N; Cook-Bolden FE; Kircik LH; Stein Gold L; Weiss J; Tyring SK; Del Rosso JQ; Guenin E
J Dermatolog Treat; 2023 Dec; 34(1):2147391. PubMed ID: 36382987
[TBL] [Abstract][Full Text] [Related]
4. Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel.
Cook-Bolden FE
J Drugs Dermatol; 2012 Apr; 11(4):455-9. PubMed ID: 22453581
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fixed-combination acne treatment in adolescents.
Gold LS
Cutis; 2013 Mar; 91(3):152-9. PubMed ID: 23617089
[TBL] [Abstract][Full Text] [Related]
6. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris.
Langner A; Chu A; Goulden V; Ambroziak M
Br J Dermatol; 2008 Jan; 158(1):122-9. PubMed ID: 18047518
[TBL] [Abstract][Full Text] [Related]
7. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne.
Callender VD
J Drugs Dermatol; 2012 May; 11(5):643-8. PubMed ID: 22527435
[TBL] [Abstract][Full Text] [Related]
8. Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel.
Eichenfield LF; Krakowski AC
J Drugs Dermatol; 2012 Jul; 11(7):818-24. PubMed ID: 22777222
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
Eichenfield LF; Alió Sáenz AB
J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
[TBL] [Abstract][Full Text] [Related]
10. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
Tanghetti E; Dhawan S; Torok H; Kircik L
Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC; Baldwin H; Stein Gold L; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
[TBL] [Abstract][Full Text] [Related]
13. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Stein Gold L; Baldwin H; Kircik LH; Weiss JS; Pariser DM; Callender V; Lain E; Gold M; Beer K; Draelos Z; Sadick N; Pillai R; Bhatt V; Tanghetti EA
Am J Clin Dermatol; 2022 Jan; 23(1):93-104. PubMed ID: 34674160
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.
Draelos ZD; Tanghetti EA;
Cutis; 2002 Feb; 69(2 Suppl):20-9. PubMed ID: 12095065
[TBL] [Abstract][Full Text] [Related]
16. Community-based trial results of combination clindamycin 1%--benzoyl peroxide 5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate to severe acne.
Kircik L
Cutis; 2007 Jul; 80(1 Suppl):10-4. PubMed ID: 17824581
[TBL] [Abstract][Full Text] [Related]
17. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study.
Hayashi N; Kurokawa I; Siakpere O; Endo A; Hatanaka T; Yamada M; Kawashima M
J Dermatol; 2018 Aug; 45(8):951-962. PubMed ID: 29905384
[TBL] [Abstract][Full Text] [Related]
18. Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.
Bhatia N; Weiss JS; Sadick N; Cook-Bolden FE; Tyring SK; Guenin E; Loncaric A; Harris S
J Drugs Dermatol; 2020 Jul; 19(7):727-734. PubMed ID: 32726105
[TBL] [Abstract][Full Text] [Related]
19. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study.
Gonzalez P; Vila R; Cirigliano M
J Cosmet Dermatol; 2012 Dec; 11(4):251-60. PubMed ID: 23174047
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies.
Del Rosso J; Sugarman J; Green L; Lain T; Levy-Hacham O; Mizrahi R; Gold LS
J Am Acad Dermatol; 2023 Oct; 89(4):719-727. PubMed ID: 37356627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
